Literature DB >> 10960492

Endothelin-1 and O2-mediated pulmonary hypertension in neonatal rats: a role for products of lipid peroxidation.

R P Jankov1, X Luo, J Cabacungan, R Belcastro, H Frndova, S J Lye, A K Tanswell.   

Abstract

We hypothesized that reactive O2 species, or their intermediary products, generated during exposure to elevated O2 lead to pathologic endothelin-1 expression in the newborn lung. Endothelin-1 expression and 8-isoprostane content (an in vivo marker of lipid peroxidation) were examined and found to be elevated (p < 0.05) in the lungs of newborn rats with abnormal lung morphology and pulmonary hypertension, as assessed by right ventricular hypertrophy, after a 14-d exposure to 60% O2. The antioxidant and lipid hydroperoxide scavenger, U74389G (10 mg/kg), given by daily i.p. injection prevented O2-dependent right ventricular hypertrophy (p < 0.05 compared with vehicle-treated controls), but had no effect on abnormal lung morphology. Additionally, we observed that 8-isoprostane caused marked endothelin-1 mRNA up-regulation in vitro in primary rat fetal lung cell cultures. We conclude that reactive O2 species, or their bioactive intermediaries, are causative in O2-mediated pulmonary hypertension and endothelin-1 up-regulation. It is likely that the bioactive lipid peroxidation product, 8-isoprostane, plays a key role in pathologic endothelin-1 expression and pulmonary hypertension during oxidant stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960492     DOI: 10.1203/00006450-200009000-00005

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  Effects of combined hyperoxia and cyclooxygenase inhibition in neonatal rat lungs.

Authors:  Katherine M Kuniyoshi; Romy S Brock; Bisrat H Gebrekristos; Matthew Abad-Santos; Dinh Hoang; Houchang D Modanlou; Brigham C Willis; Kay D Beharry
Journal:  Am J Transl Res       Date:  2010-06-08       Impact factor: 4.060

3.  Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.

Authors:  Emily Z Xu; Crystal Kantores; Julijana Ivanovska; Doreen Engelberts; Brian P Kavanagh; Patrick J McNamara; Robert P Jankov
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-01       Impact factor: 4.733

Review 4.  Role of oxidized lipids in pulmonary arterial hypertension.

Authors:  Salil Sharma; Grégoire Ruffenach; Soban Umar; Negar Motayagheni; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

5.  Isoprostanes as physiological mediators of transition to newborn life: novel mechanisms regulating patency of the term and preterm ductus arteriosus.

Authors:  Jian-Xiong Chen; Patrick W O'Mara; Stanley D Poole; Naoko Brown; Noah J Ehinger; James C Slaughter; Bibhash C Paria; Judy L Aschner; Jeff Reese
Journal:  Pediatr Res       Date:  2012-08       Impact factor: 3.756

6.  Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension.

Authors:  Christine B Bui; Magdalena Kolodziej; Emma Lamanna; Kirstin Elgass; Arvind Sehgal; Ina Rudloff; Daryl O Schwenke; Hirotsugu Tsuchimochi; Maurice A G M Kroon; Steven X Cho; Anton Maksimenko; Marian Cholewa; Philip J Berger; Morag J Young; Jane E Bourke; James T Pearson; Marcel F Nold; Claudia A Nold-Petry
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

7.  Decreased low-density lipoprotein and the presence of pulmonary arterial hypertension among newly diagnosed drug-naïve patients with systemic lupus erythematosus: D-dimer as a mediator.

Authors:  Jing Huang; Qi An; Cai-Lian Zhang; Lan He; Lei Wang
Journal:  Exp Ther Med       Date:  2022-07-27       Impact factor: 2.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.